evaluatepharma orphan drug report 2014 infographic
DESCRIPTION
Infographic based on EvaluatePharma's Orphan Drug Report 2014 - providing a top-level insight, from the world's financial markets, into the expected performance of the orphan drug market between now and 2020. Full report available to download free at www.evaluategroup.com/orphandrug2014TRANSCRIPT
Leader Board: 2020
R&D Spend vs. Return on Investment
By 2020:Worldwide orphan drug sales forecast
to be $176 billion.
Compound Annual Growth Rate
for orphan drugs will be 2x overall drug market,excluding generics.
BMYSales
Drug
R&D
Revlimid (lenalidomide)
VX-809 + Ivacaftor
BMY set to climb to #1 position in orphan drug sales in 2020
#1 orphan drug in 2020
Most valuable R&D orphan drug
Phase III orphan drug development
costs ½ that of non-orphan drugs,
potentially ¼ after US tax breaks.
Phase III orphan drugs expected ROI
to be 1.89x non-orphan drugs.
Median Cost per Patient Differential
19x higher for orphan drugs
Compared to non-orphan
$98,534 vs $5,153
$755 million | Orphan (Top 10)
Avg. USA Sales 5 Years After Launch(2013 FDA Approvals)
Avg. Phase III Trial Size(2013 FDA Approvals)
$1,755 million | Non-Orphan (Top 10)
1,310 patients | Orphan (Top 10)
Orphan Drugs
Sales 2020
Non-Orphan Drugs
Orphan drugs will be 19.1% of worldwide prescription sales, excluding generics.
Trends in Sales
Download the full report at www.evaluategroup.com/orphandrug2014Copyright @ 2014 Evaluate Ltd. All rights reserved.
6,811 patients | Non-Orphan (Top 10)
Orphan Drug Report 2014